You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Osteoporosis

Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

  • Technology appraisal guidance
  • Reference number: TA160
  • Published:  27 October 2008
  • Last updated:  07 February 2018
  • Guidance
  • Tools and resources
  • Evidence
  • History

TA160 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix A - provisional matrix of stakeholders

TA160 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix A - provisional matrix of stakeholders TA160 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix A - provisional matrix of stakeholders
27 August 2013
(102.12 Kb 29 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 23 August 2013

Back to top